Schott Gisela, Reichel Margrit, Junkermann Hans, Becker Nikolaus
Pilot Project Mammography Screening Wiesbaden, Michelsberg 3, 65183 Wiesbaden, Germany.
J Cancer Res Clin Oncol. 2008 Jan;134(1):29-35. doi: 10.1007/s00432-007-0239-4. Epub 2007 Jun 30.
Several parameters for quality assurance of mammography screening require background incidence rates, i.e. the breast cancer incidence in the absence of screening. For new programmes, incidence rates for the years prior to the programme are usually taken as a substitute with the appropriate source being cancer registries. In Germany, the feasibility of quality-assured screening was examined in three pilot projects over the years 2001-2005, so that background incidence was needed for quality assurance. Since countrywide cancer registration was not yet well established and especially in the pilot area of Wiesbaden an active cancer registry did not exist, other ways to obtain accurate rates were needed. Thus, in this pilot a manual data collection of breast cancer cases from diagnosing pathologic institutes was conducted to quantify local breast cancer incidence and compare it with available regional registry data from a distant part of the country. Results showed large similarities of rates for the mid of the 1990s, but a stronger increase of incidence for the subsequent years specifically in the pilot area. This increase was likely related to particular efforts in favour of opportunistic screening in that area. They led to increased detection of small cancers, but were too unsystematic to initiate decline of advanced breast cancers on the population level. In view of getting appropriate figures for background incidence these results indicate that emphasis should be put on using rates which are less affected by opportunistic screening rather than obtaining geographically proximate data. We propose to use the 50-69 years incidence rate of breast cancer for the years 1996-2000 in the Saarland cancer registry as background incidence rate which is almost identical to the Wiesbaden data for 1996 and 1997 but increased less strongly during 1998-2000. This incidence rate is 2.5 per 1,000, while that found in the Wiesbaden area was 2.7 per 1,000.
乳腺钼靶筛查质量保证的几个参数需要背景发病率,即无筛查情况下的乳腺癌发病率。对于新的筛查项目,通常将项目开展前几年的发病率作为替代,合适的数据源是癌症登记处。在德国,2001年至2005年期间通过三个试点项目检验了质量保证筛查的可行性,因此质量保证需要背景发病率。由于全国性癌症登记尚未完善,特别是在威斯巴登试点地区没有活跃的癌症登记处,所以需要其他方法来获取准确的发病率。因此,在这个试点中,从诊断病理机构手动收集乳腺癌病例数据,以量化当地乳腺癌发病率,并与该国偏远地区现有的区域登记数据进行比较。结果显示,20世纪90年代中期的发病率有很大相似性,但随后几年发病率上升更为明显,特别是在试点地区。这种上升可能与该地区支持机会性筛查的特别努力有关。这些努力导致小癌症的检出率增加,但过于不系统,无法在人群层面引发晚期乳腺癌发病率的下降。鉴于要获得背景发病率的合适数据,这些结果表明应强调使用受机会性筛查影响较小的发病率,而不是获取地理上相近的数据。我们建议将萨尔州癌症登记处1996 - 2000年50 - 69岁女性的乳腺癌发病率作为背景发病率,该发病率与威斯巴登1996年和1997年的数据几乎相同,但在1998 - 2000年期间增长幅度较小。该发病率为每1000人中有2.5例,而在威斯巴登地区发现的发病率为每1000人中有2.7例。